Novavax Announces First Participants in Coronavirus Vaccine Clinical Trial

News
Article

The company announced that participants have enrolled in a Phase 1/2 clinical trial of its COVID-19 vaccine candidate, NVX‑CoV2373, a prefusion protein made using Novavax’s proprietary nanoparticle technology.

Novavax, a late-stage biotechnology company located in Gaithersburg, MD, announced on May 25, 2020 that participants have enrolled in a Phase 1/2 clinical trial of its COVID-19 vaccine candidate, NVX‑CoV2373, a prefusion protein made using Novavax’s proprietary nanoparticle technology.

According to a company press release, the Phase 1 portion of the trial is a randomized, observer-blinded, placebo-controlled trial to determine the immunogenicity and safety of the vaccine candidate using a two-dose trial regimen with Matrix‑M and without. The Phase 2 section will take place in several countries and will assess immunity, safety, and the COVID‑19 disease reduction associated with the candidate.

Novavax selected NVX‑CoV2373 as its lead COVID-19 candidate after preclinical testing showed high immunogenicity and high levels of neutralizing antibodies, the press release said.

“Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVID‑19 pandemic,” said Stanley C. Erck, president and CEO of Novavax, in the press release. “We look forward to sharing the clinical results in July and, if promising, quickly initiating the Phase 2 portion of the trial.”

Source: Novavax

 

 

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content